1. Greenberg RN, Scott IJ, Vaughn HH, et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004; 17:517-525.
2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13:236-301.
3. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in the era of Aspergillus-active antifungal therapy in a tertiary care cancer center: a case-control observational study of 27 recent cases. J Infect Dis. 2005; 19:1350-1359.
4. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000; 30:851-860.
5. Richardson MD, Kaukila PK, Shankland GS. Rhizopus, Rhizomucor, Absidid, and other agents of systemic and subcutaneous Zygomycetes. In: Murray PR, ed.Manual of Clinical Microbiology. 8th ed. Washington, DC: ASM Press; 2003; 1761-1780.